Apheresis in hematologic and oncologic disease.
Therapeutic bloodletting dates back to ancient times. With the development of sophisticated in vivo cell separators, it has become an established and effective modality in the treatment of a number of hematologic-oncologic diseases. Apheresis must, however, be used with discrimination--only when more conservative measures have proved inadequate.
D000744:Anemia, Hemolytic, Autoimmune / Q000628:therapy; D001809:Blood Viscosity; D002469:Cell Separation / Q000379:methods*; D003449:Cryoglobulinemia / Q000628:therapy; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D007938:Leukemia / Q000628:therapy*; D007943:Leukemia, Hairy Cell / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000628:therapy; D010956:Plasmapheresis / Q000379:methods*; D010983:Plateletpheresis / Q000379:methods*; D008258:Waldenstrom Macroglobulinemia / Q000628:therapy